BIOCYTOGEN-B (02315) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of RMB 621 million, representing a year-on-year increase of 51.3%. Profit attributable to shareholders reached RMB 47.999 million, turning from loss to profit compared to the same period last year. Earnings per share stood at RMB 0.12.

After years of strategic positioning, the company has established a dual-engine business ecosystem driven by preclinical products & services and antibody discovery. These two major segments achieve bidirectional empowerment through technological synergy and resource coordination, continuously releasing growth momentum. The company consistently relies on R&D to drive business development, continuously providing domestic and international biopharmaceutical enterprises with globally competitive, high-quality R&D products and services.

In the first half of 2025, the preclinical products and services business, centered on innovative animal model sales, achieved operating revenue of RMB 458 million, an increase of 56.9% compared to the same period last year, while maintaining a high gross margin of approximately 70%. As another core driver of the company's performance growth, the antibody discovery business achieved operating revenue of RMB 163 million in the first half of 2025, an increase of 37.8% compared to the same period last year, with a gross margin of approximately 90%.

As of June 30, 2025, the company has cumulatively signed approximately 280 therapeutic antibody and various clinical asset collaboration/licensing/transfer agreements, and has reached RenMice® platform licensing development collaborations with partners including multiple multinational pharmaceutical companies (MNCs). During the first half of 2025, approximately 80 new contracts were signed, representing an increase of about 60% compared to the same period last year. In the future, the company will gradually increase the transfer volume of PCC molecules to obtain higher upfront payments, milestones, and sales royalties.

On one hand, based on the established global network system, the company continued to expand overseas markets in the first half of 2025, further expanding its sales team and improving its sales system. Overseas business continued to maintain rapid growth, achieving operating revenue of RMB 422 million. On the other hand, the recovery of the domestic biopharmaceutical industry has driven biopharmaceutical companies to release more R&D demands. The company leveraged its innovative and high-quality products and services to better meet customer needs, achieving high-speed growth in domestic business in the first half of 2025, with operating revenue of RMB 200 million. The global positioning enables the company's business to have stronger resilience and risk resistance capabilities, allowing it to achieve steady growth through cycles.

The company has long maintained high-level R&D investment to build technological barriers and continuously improved R&D efficiency to achieve more efficient transformation from innovative R&D to production, continuously launching innovative, high-quality products and services to meet customer demands. In the first half of 2025, the company's R&D expenses were RMB 209 million, an increase of RMB 47.4 million compared to the same period last year, with an R&D expense ratio exceeding 30%. At the same time, the company persistently implements lean management to improve operational efficiency, with management expense ratios continuously declining. The series of "revenue generation and cost reduction" measures that began in 2023 have achieved significant results.